- Published on
Emergency And Acute Medicine: Hypoglycemic Agent Poisoning
Basics
Description Hypoglycemic agent poisoning results from oral or parenteral agents that cause hypoglycemia or metabolic derangements. Poisoning may be intentional or accidental.
Etiology
Insulin Enhances cellular glucose uptake, limits cerebral glucose availability, and shifts potassium intracellularly causing hypokalemia.
Sulfonylureas And Meglitinides Increase pancreatic insulin release, reduce hepatic glucose production, and increase peripheral insulin sensitivity. Effects are potentiated by polypharmacy, alcohol use, hepatic dysfunction, and renal insufficiency.
GLP-1 Modulators Exenatide and DPP-4 inhibitors (e.g., sitagliptin, saxagliptin) enhance insulin secretion and delay gastric emptying. Effects in overdose are unclear.
Biguanides (Metformin) Rarely cause hypoglycemia alone but, with insulin, increase cellular glucose uptake, inhibit gluconeogenesis, reduce GI glucose absorption, and promote lactate accumulation leading to lactic acidosis.
Thiazolidinediones Increase insulin sensitivity and glucose uptake in the presence of insulin.
α-Glucosidase Inhibitors Reduce carbohydrate absorption and systemic glucose.
Diagnosis
Signs And Symptoms
Insulin Or Sulfonylureas Hypoglycemia often when glucose <40–60 mg />L. Symptoms include diaphoresis, pallor, tremor, hunger, nausea, headache, blurred vision, paresthesias, weakness, anxiety, confusion, seizures, coma, tachycardia or late bradycardia, hypertension, and hypothermia. β-blockers may blunt adrenergic signs.
Biguanides Lactic acidosis with nausea, vomiting, abdominal pain, agitation, lethargy, coma, Kussmaul respirations, hypotension, and tachycardia.
Pediatric Considerations Neonatal hypoglycemia may occur after maternal sulfonylurea use. Ingestion of a single sulfonylurea tablet can cause severe hypoglycemia or death. Onset may be delayed up to 8 hr.
History
Diabetes diagnosis, access to medications, dosing errors, renal or hepatic disease, alcohol use, and possible malicious or intentional ingestion.
Physical Exam Tachycardia (may be blunted), altered mental status, ataxia, seizures, or coma.
Essential Workup
Frequent glucose monitoring, vital signs, and neurologic assessment. Check electrolytes and lactate for biguanides and liver function tests for thiazolidinediones.
Diagnosis Tests And Interpretation
Lab Serum glucose pre- and post-treatment, electrolytes (hypokalemia, anion gap acidosis), BUN/creatinine, CBC, ethanol level, lactate, LFTs, ABG. Insulin and C-peptide levels may confirm exogenous insulin use.
Imaging/Other ECG for dysrhythmias, EEG for persistent coma, CT head for prolonged hypoglycemia, CXR for aspiration or pulmonary edema.
Differential Diagnosis Adrenal insufficiency, panhypopituitarism, sepsis, insulinoma, neuroendocrine tumors, cirrhosis, ethanol or salicylate ingestion, β-blocker overdose, Ackee fruit poisoning.
Treatment
Prehospital Transport medications and pill bottles with patient.
Initial Stabilization/Therapy ABCs, oxygen, IV access, cardiac monitoring, pulse oximetry. Give naloxone, thiamine, and dextrose if altered mental status.
Emergency Department Treatment/Procedures Treat hypoglycemia with IV dextrose bolus followed by D5W or D10W infusion. Allow oral intake when mental status improves. Persistent neuroglycopenia requires repeat dextrose. Consider activated charcoal for recent oral ingestions. Treat hypotension with IV fluids and cautious vasopressors. Give bicarbonate for severe metformin-associated acidosis (pH <7). use benzodiazepines for seizures. sulfonylurea-induced recurrent hypoglycemia, inhibit insulin secretion with octreotide or diazoxide. consider early hemodialysis severe biguanide-associated lactic acidosis.< />pan>
Medications
Activated charcoal 1 g/kg PO. Dextrose 50–100 mL D50 IV (peds: D25 2 mL/kg). Octreotide 50–100 μg SC/IV q8–12h. Diazoxide 200 mg PO or 1–3 mg/kg IV. Glucagon 1–2 mg IM/SC/IV. Benzodiazepines for seizures. Thiamine 100 mg IV/IM.
Follow-Up And Disposition
Admission Criteria
Sulfonylurea or long-acting insulin exposure, recurrent or refractory hypoglycemia, need for continuous dextrose infusion, intentional overdose, all pediatric sulfonylurea ingestions, or metabolic complications from biguanides.
Discharge Criteria
Short-acting insulin error with dietary insufficiency, normal mental status, stable glucose after ≥4 hr observation, and tolerating oral intake.
Issues For Referral Poison prevention counseling for accidental exposure; psychiatric evaluation for intentional poisoning.
Follow-Up Recommendations
Close outpatient follow-up for glucose monitoring and medication adjustment.
Pearls And Pitfalls Sulfonylureas have prolonged effects with delayed or recurrent hypoglycemia—observe carefully. Metformin must be withheld 48 hr after IV contrast due to lactic acidosis risk. Persistent hypoglycemia requires octreotide, not repeated dextrose alone.
Basics
Description Hypoglycemic agent poisoning results from oral or parenteral agents that cause hypoglycemia or metabolic derangements. Poisoning may be intentional or accidental.
Etiology
Insulin Enhances cellular glucose uptake, limits cerebral glucose availability, and shifts potassium intracellularly causing hypokalemia.
Sulfonylureas And Meglitinides Increase pancreatic insulin release, reduce hepatic glucose production, and increase peripheral insulin sensitivity. Effects are potentiated by polypharmacy, alcohol use, hepatic dysfunction, and renal insufficiency.
GLP-1 Modulators Exenatide and DPP-4 inhibitors (e.g., sitagliptin, saxagliptin) enhance insulin secretion and delay gastric emptying. Effects in overdose are unclear.
Biguanides (Metformin) Rarely cause hypoglycemia alone but, with insulin, increase cellular glucose uptake, inhibit gluconeogenesis, reduce GI glucose absorption, and promote lactate accumulation leading to lactic acidosis.
Thiazolidinediones Increase insulin sensitivity and glucose uptake in the presence of insulin.
α-Glucosidase Inhibitors Reduce carbohydrate absorption and systemic glucose.
Diagnosis
Signs And Symptoms
Insulin Or Sulfonylureas Hypoglycemia often when glucose <40–60 mg />L. Symptoms include diaphoresis, pallor, tremor, hunger, nausea, headache, blurred vision, paresthesias, weakness, anxiety, confusion, seizures, coma, tachycardia or late bradycardia, hypertension, and hypothermia. β-blockers may blunt adrenergic signs.
Biguanides Lactic acidosis with nausea, vomiting, abdominal pain, agitation, lethargy, coma, Kussmaul respirations, hypotension, and tachycardia.
Pediatric Considerations Neonatal hypoglycemia may occur after maternal sulfonylurea use. Ingestion of a single sulfonylurea tablet can cause severe hypoglycemia or death. Onset may be delayed up to 8 hr.
History
Diabetes diagnosis, access to medications, dosing errors, renal or hepatic disease, alcohol use, and possible malicious or intentional ingestion.
Physical Exam Tachycardia (may be blunted), altered mental status, ataxia, seizures, or coma.
Essential Workup
Frequent glucose monitoring, vital signs, and neurologic assessment. Check electrolytes and lactate for biguanides and liver function tests for thiazolidinediones.
Diagnosis Tests And Interpretation
Lab Serum glucose pre- and post-treatment, electrolytes (hypokalemia, anion gap acidosis), BUN/creatinine, CBC, ethanol level, lactate, LFTs, ABG. Insulin and C-peptide levels may confirm exogenous insulin use.
Imaging/Other ECG for dysrhythmias, EEG for persistent coma, CT head for prolonged hypoglycemia, CXR for aspiration or pulmonary edema.
Differential Diagnosis Adrenal insufficiency, panhypopituitarism, sepsis, insulinoma, neuroendocrine tumors, cirrhosis, ethanol or salicylate ingestion, β-blocker overdose, Ackee fruit poisoning.
Treatment
Prehospital Transport medications and pill bottles with patient.
Initial Stabilization/Therapy ABCs, oxygen, IV access, cardiac monitoring, pulse oximetry. Give naloxone, thiamine, and dextrose if altered mental status.
Emergency Department Treatment/Procedures Treat hypoglycemia with IV dextrose bolus followed by D5W or D10W infusion. Allow oral intake when mental status improves. Persistent neuroglycopenia requires repeat dextrose. Consider activated charcoal for recent oral ingestions. Treat hypotension with IV fluids and cautious vasopressors. Give bicarbonate for severe metformin-associated acidosis (pH <7). use benzodiazepines for seizures. sulfonylurea-induced recurrent hypoglycemia, inhibit insulin secretion with octreotide or diazoxide. consider early hemodialysis severe biguanide-associated lactic acidosis.< />pan>
Medications
Activated charcoal 1 g/kg PO. Dextrose 50–100 mL D50 IV (peds: D25 2 mL/kg). Octreotide 50–100 μg SC/IV q8–12h. Diazoxide 200 mg PO or 1–3 mg/kg IV. Glucagon 1–2 mg IM/SC/IV. Benzodiazepines for seizures. Thiamine 100 mg IV/IM.
Follow-Up And Disposition
Admission Criteria
Sulfonylurea or long-acting insulin exposure, recurrent or refractory hypoglycemia, need for continuous dextrose infusion, intentional overdose, all pediatric sulfonylurea ingestions, or metabolic complications from biguanides.
Discharge Criteria
Short-acting insulin error with dietary insufficiency, normal mental status, stable glucose after ≥4 hr observation, and tolerating oral intake.
Issues For Referral Poison prevention counseling for accidental exposure; psychiatric evaluation for intentional poisoning.
Follow-Up Recommendations
Close outpatient follow-up for glucose monitoring and medication adjustment.
Pearls And Pitfalls Sulfonylureas have prolonged effects with delayed or recurrent hypoglycemia—observe carefully. Metformin must be withheld 48 hr after IV contrast due to lactic acidosis risk. Persistent hypoglycemia requires octreotide, not repeated dextrose alone.
0 Comments
